Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference 2019
A live webcast of the presentation will be available on the "Investors & Media" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the event.
Kodiak™ is a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ merges the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. In addition to its lead product candidate, KSI-301, a novel anti-VEGF antibody biopolymer conjugate in clinical development for the treatment of age-related macular degeneration and diabetic retinopathy, Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases such as wet AMD and diabetic retinopathy. Kodiak is based in
View original content to download multimedia:http://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-the-bank-of-america-merrill-lynch-health-care-conference-2019-300846916.html
John Borgeson, Senior Vice President and Chief Financial Officer, Tel (650) 281-0850, email@example.com